Fate Therapeutics (FATE) Gains from Investment Securities (2012 - 2013)

Fate Therapeutics (FATE) posted Gains from Investment Securities of $29000.0 for Q4 2013, up 193.55% on a QoQ basis from -$31000.0 in Q3 2013, and up 1550.0% year-over-year from $1757.6 in Q4 2012.

Fate Therapeutics (FATE) Gains from Investment Securities (2012 - 2013) Analysis & Trends

Fate Therapeutics' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $29000.0 for Q4 2013.

  • Quarterly Gains from Investment Securities rose 1550.0% year-over-year to $29000.0 in Q4 2013, while the trailing twelve-month figure through Dec 2017 was $20000.0 (changed N/A YoY) and the FY2017 annual result came in at $30000.0, changed N/A from the prior year.
  • Gains from Investment Securities was $29000.0 for Q4 2013 at Fate Therapeutics, up from -$31000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $29000.0 in Q4 2013 and bottomed at -$31000.0 in Q3 2013.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 65,719.23 Bn 65,718.94 Bn -
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 471.85 Bn 467.06 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.29 Bn 115.04 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.04 Bn 61.28 Bn 3.31 Bn
7 Belite Bio 62.06 Bn 62.06 Bn -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.47 Bn 34.47 Bn 959.66 Mn
10 Fate Therapeutics 290.46 Mn 290.46 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2013 29,000.00
Dec 31, 2013 29,000.00
Sep 30, 2013 -31,000.00
Sep 30, 2013 -31,000.00
Jun 30, 2013 22,000.00
Jun 30, 2013 22,000.00
Mar 31, 2013 -12,000.00
Mar 31, 2013 -12,000.00
Dec 31, 2012 -2,000.00
Dec 31, 2012 -2,000.00